Stock Analysis·← Pickers

BNTC

Benitec Biopharma Inc.

Benitec Biopharma Inc. (BNTC) is currently in a range/mixed trend, trading above both the 50-day and 200-day moving averages. RSI is at 55.5, with 2/3 trend checks passing.

Price
$13.02
2026-07-16
Trend score
2/3
Range / Mixed
RSI (14)
55.5
Neutral
Price above MA50Price above MA200MA50 above MA200
Change stock
Search another ticker to view its stock analysis page.
Chart View

BNTC with MA50 and MA200

16.5214.9013.2911.6810.0607/3110/2401/2204/1707/15
BNTC2025-07-312026-07-15
PriceMA50MA200
Technical Indicators

Key levels & signals

MA50
$11.95+8.95% vs price
MA200
$12.50+4.15% vs price
RSI (14)
55.5Neutral zone
MACD Signal
BearishMomentum below signal
Macro Support
$9.85–$10.0023.2% below price · 4 touches
Support Quality
4 touches1.2× zone volume
Chart Summary
Trend summary for BNTC

Benitec Biopharma Inc. (BNTC) looks more range-bound than strongly trending, but there are still a few supportive signs on the chart. The latest available price is $13.02, and 2 of 3 core trend checks are currently passing. Price is trading above the 50-day moving average by 8.9% and above the 200-day moving average by 4.1%.

Momentum and stretch context

BNTC currently has an RSI reading of 55.5, which leans mildly positive without looking too stretched. In other words, momentum is supportive, but not yet extreme enough to dominate the entire chart read.

What traders may watch next

This page is designed to help you quickly understand what the BNTC chart looks like before opening the full dashboard. The aim is not to tell you what to buy or sell, but to make it easier to judge whether the stock is trending cleanly, becoming stretched, or simply moving in a more awkward range.

Company profile

About Benitec Biopharma Inc.

Benitec Biopharma Inc. is an emerging biotechnology firm dedicated to advancing groundbreaking genetic medicines. The company specializes in DNA-directed RNA interference (RNAi) based treatments, which it develops to address severe and enduring human conditions. Its pipeline features BB-301, an adeno-associated virus (AAV) gene therapy aimed at treating oculopharyngeal muscular dystrophy, and BB-103, designed to combat chronic hepatitis B virus infection. Established in 1995, Benitec Biopharma's main operations are situated in Hayward, California.

Sector
Healthcare
Industry
Biotechnology
CEO
Jerel A. Banks
Employees
19
Market cap
$341.7M
Beta
0.25
52-week range
$9.85 – $16.76
Dividend
Yes · $0.77
Exchange
NASDAQ
Country
US
IPO date
24 Jun 2014
ISIN
US08205P2092
CUSIP
08205P209
Company profile data from Financial Modeling Prep. BNTC listed on NASDAQ.
Share dilution

BNTC shares outstanding over time

Tracking total shares outstanding is one way to spot dilution — a rising line means the company has issued more shares (stock-based compensation, secondary offerings, convertible debt), which spreads the same earnings and ownership across more shares. A falling line usually reflects buybacks.

Jun 2019Mar 2026
Shares outstanding (latest)
49.4M
Since Jun 2019
+24398.1%
Trend
More shares outstanding
Historical shares-outstanding data from Financial Modeling Prep. BNTC28 data points from Jun 2019 to Mar 2026.
Learn More

Learn the indicators behind this page

Explore More

More stock opportunities

FAQ

Common questions about BNTC

Is this page a buy or sell recommendation?

No. This page is designed to help you review chart structure, momentum and technical context more quickly, but it is not personal financial advice.

Why can a stock look bullish and overbought at the same time?

Strong trending stocks can still become stretched in the short term. That is why trend traders and dip buyers can read the same chart differently.

What should I do next after reading this page?

Open the full dashboard, review the chart in more detail, compare indicators, and decide whether the setup still makes sense within your own process.